

NATURAL HEALTH PRODUCT

L-ARGININE

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.

Notes

- Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion.
- The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant.

Date

May 31, 2024

Proper name(s), Common name(s), Source information

Table 1. Proper name(s), Common name(s), Source information

Proper name(s)	Common name(s)	Source information	
		Source ingredient(s)	Preparation(s)
<ul style="list-style-type: none"> • (S)-2-Amino-5-[(aminoiminomethyl)amino] pentanoic acid • L-Arginine 	L-Arginine	<ul style="list-style-type: none"> • DL-Arginine • L-Arginine • L-Arginine alpha-ketoglutarate • L-Arginine ketoisocaproic acid • L-Arginine monohydrochloride 	Synthetic

References: Proper names: NIH 2023; RSC 2023; Common name: NIH 2023; RSC 2023; Source information: NIH 2023; USP-NF 2023; BP 2009; Ph. Eur. 2007.

Route of administration

Oral

Dosage form(s)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.



Acceptable dosage forms for oral use are indicated in the dosage form drop-down list of the web-based Product Licence Application form for Compendial applications..

Use(s) or Purpose(s)

- May help support a modest improvement in exercise capacity in individuals with stable cardiovascular diseases (CVD) (Doutreleau et al. 2010; Doutreleau et al. 2006; Lim et al. 2004; Palloshi et al. 2004; Bode- Böger et al. 2003; Lekakis et al. 2002; Sydow et al. 2002; Nagaya et al. 2001; Bednarz et al. 2000; Hambrecht et al. 2000; Tangphao et al. 1999; Lerman et al. 1998; Clarkson et al. 1996; Rector et al. 1996).
- L-Arginine is (a non-essential amino acid) involved in protein synthesis (Shils et al. 2006; IOM 2005; Groff and Gropper 2000).

Dose(s)

Subpopulation(s)

Adults 18 years and older

Quantity(ies)

Improvement in exercise capacity in individuals with stable CVD

6 - 21 grams of L-Arginine, per day; Not to exceed 8 grams per single dose (Doutreleau et al. 2010; Shao and Hathcock 2008; Doutreleau et al. 2006; Evans et al. 2004; Lim et al. 2004; Palloshi et al. 2004; Bode-Bogër et al. 2003; Bednarz et al. 2000; Hambrecht et al. 2000; Lerman et al. 1998; Adams et al. 1997; Ceremużyński et al. 1997; Clarkson et al. 1996; Rector et al. 1996).

Protein synthesis

0.21 - 21 grams of L-Arginine, per day; Not to exceed 8 grams per single dose (Shao and Hathcock 2008; IOM 2005; Evans et al. 2004; Bode-Bogër et al. 2003; Sydow et al. 2002).

Direction(s) for use

No statement required.

Duration(s) of use

Products providing 3 g to 9 g of L-Arginine, per day

Ask a health care practitioner/health care provider/health care professional/doctor/physician for



use beyond 8 weeks if you have a cardiovascular disease (Salmani et al. 2021; Shao and Hathcock 2008; Sydow et al. 2002; Hambrecht et al. 2000; Clarkson et al. 1996; Rector et al. 1996).

Products providing more than 9 g and up to 14 g of L-Arginine, per day

Ask a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 8 weeks if you have a cardiovascular disease or beyond 6 months if you are healthy (Alexander et al. 2005; De Nicola et al. 1999).

Products providing more than 14 g of L-Arginine, per day

Ask a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 8 weeks if you have a cardiovascular disease or beyond 12 weeks if you are healthy (Tangphao et al. 1999).

Risk information

Caution(s) and warning(s)

All products

Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

Improvement in exercise capacity in individuals with stable CVD

Ask a health care practitioner/health care provider/health care professional/doctor/physician if your symptoms worsen.

Products providing more than 0.42 g of L-Arginine, per day

- **Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).**
- **Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).**

Contraindication(s)

Products providing more than 9 g of L-Arginine, per day



Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).

Known adverse reaction(s)

Products providing more than 9 g of L-Arginine, per day

When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).

Non-medicinal ingredients

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

Storage conditions

Must be established in accordance with the requirements described in the *Natural Health Products Regulations*.

Specifications

- The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide.
- The medicinal ingredient must comply with the requirements outlined in the NHPID.



EXAMPLE OF PRODUCT FACTS:

Consult the Guidance Document, [Labelling of Natural Health Products](#) for more details.

Product Facts	
Medicinal ingredient in each capsule	
L-Arginine (L-arginine monohydrochloride)	XX mg
Uses	
<ul style="list-style-type: none"> • May help support a modest improvement in exercise capacity in individuals with stable cardiovascular diseases (CVD). • L-Arginine is a non-essential amino acid involved in protein synthesis. 	
Warnings	
If applicable¹:	
Allergens: food allergen, gluten (gluten source), sulphites	
Contains aspartame	
Do not use if you have had a heart attack ² .	
Ask a health care practitioner before use if • you are pregnant or breastfeeding • you have a cardiovascular disease and are attempting an increase in physical activity ³ • you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners ³ .	
When using this product you may experience gastrointestinal discomfort ² .	
Ask a health care practitioner if your symptoms worsen ⁴ .	
Directions	
Adults 18 years and older: • Take X capsule(s), X time(s) a day • Ask a health care practitioner for use beyond 8 weeks if you have a cardiovascular disease ⁵ • for use beyond 8 weeks if you have a cardiovascular disease or beyond 6 months if you are healthy ⁶ • for use beyond 8 weeks if you have a cardiovascular disease or beyond 12 weeks if you are healthy ⁷ .	
Other information	
(Add storage information)	
Non-medicinal ingredients	
List all NMIs	
Questions? (Call) 1-XXX-XXX-XXXX	

¹ This section can be removed from the table if the product contains no allergen or aspartame.

² Products providing more than 9 g of L-Arginine, per day.

³ Products providing more than 0.42 g of L-Arginine, per day.

⁴ The qualifier ‘For the improvement in exercise capacity in individuals with stable CVD:’ may be added to the label to inform consumers.

⁵ Products providing 3 g to 9 g of L-Arginine, per day.

⁶ Products providing more than 9 g and up to 14 g of L-Arginine, per day.

⁷ Products providing more than 14 g of L-Arginine, per day.

References cited

Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. 1997. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to the endothelial cells in young men with coronary artery disease. *Atherosclerosis* 129(2):261-269.



Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. 1995. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. *Journal of the American College of Cardiology* 26(4):1054-1061.

Alexander JW, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R, Cardi MA, Austin JN, Goel S, Safdar S, Greenberg N, Chen X, Woodle ES. 2005. The influence of immunomodulatory diets on transplant success and complications. *Transplantation* 79:460-465.

Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. 2005. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. *Kardiol Pol.* 62(5):421-7.

Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. 2000. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. *International Journal of Cardiology* 75(2-3):205-210.

Bode-Böger SM, Muke J, Surdacki A, Brobant G, Böger RH, Frölich J. 2003. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. *Vascular Medicine* 8(2):77-81.

BP 2009: British Pharmacopoeia Commission. 2008. *British Pharmacopoeia 2009, Volume II*. London (GB): The Stationary Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).

Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. 1997. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. *The American Journal of Cardiology* 80(3):331-333.

Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. 1996. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. *Journal of Clinical Investigation* 97(8):1989-1994.

De Nicola L, Bellizzi V, Minutolo R, Andreucci M, Capuano A, Garibotto G, Corso G, Andreucci VE, Cianciaruso B. 1999. Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. *Kidney International* 56:674-684.

Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. 2010. L-Arginine supplementation improves exercise capacity after a heart transplant. *American Journal of Clinical Nutrition*. Doi: 10.3945/ajcn.2009.27881.

Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. 2006. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. *International Journal of Sports Medicine* 27(7):567-572.

Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. 2004. Biochemical responses



of healthy subjects during dietary supplementation with L-arginine. *Journal of Nutritional Biochemistry* 15(9):534-539.

Grimble GK. 2007. Adverse gastrointestinal effects of arginine and related amino acids. *The Journal of Nutrition* 137(6 Suppl 2):1693S-1701S.

Groff J, Gropper S. 2000. *Advanced Nutrition and Human Metabolism*, 3rd edition. Belmont (CA): Wadsworth/Thomson Learning.

Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N, Schuler. 2000. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. *Journal of the American College of Cardiology* 35(3):706-713.

Huynh NT, Tayek JA. 2002. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. *American College of Nutrition* 21(5):422-427.

IOM 2006: Otten JJ, Pitzel Hellwig J, Meyers LD, editors. 2006. *Institute of Medicine Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. Washington (DC): National Academies Press.

IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. 2005. *Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate*. Washington (DC): National Academies Press.

Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, Dage AG, Stamatelopoulos K, Protogerou A, Stamatelopoulos SF. 2002. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. *International Journal of Cardiology* 86(2-3):317-323.

Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes Jr DR. 1998. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. *Circulation* 97(21):2123-2128.

Lim SD, Mooradian SJ, Goldberg CS, Gomez C, Crowley DC, Rocchini AP, Charpie JR. 2004. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. *The American Journal of Cardiology* 94(6):828-831.

Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. 2001. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine* 163(4):887-891.

NIH 2023: National Institutes of Health. PubChem. Bethesda (MD): National Library of Medicine, US Department of Health & Human Services. [Accessed 2023 October 23]. Available

from: <https://pubchem.ncbi.nlm.nih.gov/>

Palloshi A, Fragasso G, Piatti P, Monti LD, Setola E, Valsecchi G, Galluccio E, Chierchia SL, Morgonato A. 2004. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. *The American Journal of Cardiology* 93(7):933-935.

Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. 2002. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. *Journal of the American College of Cardiology* 39(7):1199-1203.

Ph. Eur. 2007: European Pharmacopoeia Commission. 2007. European Pharmacopoeia, 6th edition, Volume 1. Strasbourg (FR): Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM).

Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. 1996. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. *Circulation* 93(12):2135-2141.

RSC 2023: Royal Society of Chemistry: The Merck Index Online [Accessed 2023 August 14]. Available from: <https://merckindex.rsc.org/>

Salmani M, Alipoor E, Navid H, Farahbakhsh P, Yaseri M, Imani H. 2021. Effect of L-arginine on cardiac reverse remodeling and quality of life in patients with heart failure. *Clin Nutr.* 40(5):3037-3044.

Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. 2006. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. *Journal of American Medical Association* 295(1):58-64.

Shao A, Hathcock JN. 2008. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. *Regulatory Toxicology and Pharmacology* 50:376-399.

Shils ME, Olson JA, Shike M, Ross AC, editors. *Modern Nutrition in Health and Disease*, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins; 2006.

Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. 2000. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. *American Journal of Hypertension* 13(5):547-551.

Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. 2009. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. *Clin Cardiol.* 32(11):649-52.

Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, Frölich, Böger RH.



2002. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. *Cardiovascular Research* 57(1):244-252.

Tangphao O, Chalon S, Moreno H Jr, Hoffman BB, Blaschke TF. Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. *Clinical Science* 96:199-207.

USP-NF 2023: United States Pharmacopeial Convention. 2009. United States Pharmacopeia and the National Formulary. Rockville (MD): United States Pharmacopeial Convention, Inc.; 2023.

References reviewed

Abel T, Knechtle B, Perret C, Eser P, von Arx P, Knecht H. 2007. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism: A randomized, double-blind, placebo-controlled study. *International Journal of Sports Medicine* 26(5):344-349.

Andrés A, Morales JM, Prega M, Campo C, Lahera V, García-Robles R, Rodicio JL, Ruilope LM. 1997. L-arginine reverses the antinatriuretic effect of cyclosporine in renal transplant patients. *Nephrology Dialysis Transplantation* 12(7):1437-1440.

Becker Y, Olshevsky U, Levitt J. 1967. The role of arginine in the replication of Herpes simplex virus. *The Journal of General Virology* 1(4):471-478.

Bednarz B, Jaxa-Chamiec T, Gębalska J, Herbaczyńska-Cedro K, Ceremużyński L. 2004. L-Arginine supplementation prolongs duration of exercise in congestive heart failure. *Kardiologia Polska* 60(4):348-353.

Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbaneck T, Drozdowska D, Gessek J, Laskowski H. 2005. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of multicenter, randomised, double-blind, placebo-controlled ARAMI pilot trial. *Kardiologia Polska* 62(5):421-427.

Blum A, Cannon III RO, Costello R, Schenke WH, Csako G. 2000. Endocrine and lipid effects of oral L-arginine treatment in healthy postmenopausal women. *The Journal of Laboratory and Clinical Medicine* 135(3):231-237.

Blum A, Hathaway L, Mincemoyer RN, Schenke WH Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon III RO. 1999. Oral L-arginine in patients with coronary artery disease on medical management. *Circulation* 101(18):2160-2464.

Blum A, Porat R, Rosenchein Uri, Keren G, Roth A, Laniado S, Miller H. 1999. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. *American Journal of Cardiology* 83(10):1488-1490.



Cannon RA III. 2002. Oral L-arginine (and other active ingredients) for ischemic heart disease? *Journal of the American College of Cardiology* 39(1):46-48.

Carrier M, Pellerin M, Pagé PL, Searle NR, Martineau R, Caron C, Solymoss C, Pelletier LC. 1998. Can L-arginine improve myocardial protection during cardioplegic arrest? Results of phase I pilot study. *The Annals of Thoracic Surgery* 66(1):108-112.

Carrier M, Pellerin M, Perrault LP, Bouchard D, Pagé P, Searle N, Lavoie J. 2002. Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. *The Annals of Thoracic Surgery* 73(3):837-842.

Cartledge JJ, Davies AM, Eardley I. 2000. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. *BJU International* 85(4):421-426.

Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. 1999. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. *BJU International* 83(3):269-273.

Coman D, Yapliito-Lee J, Boneh A. 2008. New indications and controversies in arginine therapy. *27(4):489-496.*

Dangas G, Kuepper F. 2002. Restenosis: Repeat narrowing of a coronary artery. *Circulation* 105(22):2586-2587.

Dinh H, Nathan L. 2002. Medroxyprogesterone acetate does not antagonize estrogen-induced increases in endothelium-dependent vasodilation: potential clinical implications. *American Society for Reproductive Medicine* 78(1):122-127.

Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. 2007. L-Arginine supplementation in patients with gestational hypertension: a pilot study. *Hypertension in Pregnancy* 26(1):121-130.

Fahs CA, Heffernan KS, Fernhall B. 2009. Hemodynamic and vascular response to resistance exercise with L-arginine. *Medicine and Science in Sports and Exercise* 41(4):773-779.

Faldetta MC, Laurenti O, Desideri G, Bravi MC, De Luca O, Marinucci MC, De Mattai G, Ferri C. 2002. L-Arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients. *Diabetologia* 45(8):1120-1127.

Fricke O, Baecker N, Heer M, Tutlewski B, Schoenau E. 2008. The effect of L-arginine administration on muscle force and power in postmenopausal women. *Clinical Physiology and Functional Imaging* 28(5):307-311.



Garhöfer G, Resh H, Lung S, Weigert G, Schmetterer L. 2005. Intravenous administration of Larginine increases retinal and choroidal blood flow. *American Journal of Ophthalmology* 140(1):69-76.

Gornik HL, Creaher MA. 2004. Arginine and endothelial and vascular health. *Journal of Nutrition* 134(10 Suppl):2880S-2887S.

Griffith RS, DeLong DC, Nelson JD. 1981. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. *Chemotherapy* 27(3):209-213.

Inglis VBM. 1968. Requirement of arginine for the replication of herpes virus. *The Journal of General Virology* 3(1):9-17.

Jahangir E, Handy D, Palmisano J, Loscalzo J. 2009. The effect of L-arginine and creatine on vascular function and homocysteine metabolism. *Vascular Medicine* 14(3): 239-248.

Kiziltepe U, Tunçtan B, Eyileten ZB, Sirlak M, Arikbuku M, Tasoç R, Uysalel A, Ozyurda U. 2004. Efficiency of L-arginine enriched cardioplegia and non-cardioplegic reperfusion in ischemic hearts. *International Journal of Cardiology* 97(1):93-100.

Klotz T, Mathers MJ, Braun M, Bloch W, Engelmann U. 1999. Effectiveness of Oral L-Arginine in First-Line Treatment of Erectile Dysfunction in a Controlled Crossover Study. *Urologia Internationalis* 63(4):220-223.

Lauer T, Kleinbongart P, Rath J, Schultz R, Kelm M, Rassaf T. 2008. L-Arginine preferentially dilates stenotic segments of coronary arteries thereby increasing coronary flow. *Journal of Internal Medicine* 264(3):237-244.

Lebret T, Hervé JM, Gorny P, Worcel M, Botto H. 2002. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. *European Urology* 41(6):608-613.

Lee J, Ryu H, Farrante RJ, Morris SM Jr, Ratan RR. 2003. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. *Neuroscience* 100(8):4843-4848.

Loi C, Zazzo JF, Delpierre E, Niddam C, Neveux N, Curis E, Arnaud-Bettandier F, Cynober L. 2009. Increasing plasma glutamine in postoperative patients fed an arginine-rich immune-enhancing diet-A pharmacokinetic randomized controlled study. *Critical Care Medicine* 37(2):501-509.

Loscalzo J. 2000. What we know and don't know about L-arginine and NO. *Circulation* 101(18):2126-2129.

Loscalzo J. 2003. Adverse effects of supplemental L-arginine in atherosclerosis: Consequences



of methylation stress in a complex catabolism? *Arteriosclerosis & thrombosis and Vascular Biology* 23(1):3-5.

Lucotti P, Setola E, Monti LD, Galluccio E, Costa S, Sandoli EP, Fermo I, Rabaiotti G, Gatti R, Piatti PM. 2006. Beneficial effects of long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. *American Journal of Physiology, Endocrinology and Metabolism* 291(5):906-912.

Marchesi S, Lupattelli G, Siepi D, Roscini AR, Vaudo G, Sinzinger H, Monnarino E. 2001. Oral L-arginine administration attenuates postprandial endothelial dysfunction in young healthy males. *Journal of Clinical Pharmacy and Therapeutics* 26(5):343-349.

Mariotti F, Huneau JF, Szczepanski I, Petzke KJ, Aggoun Y, Tomé D, Bonnet D. 2007. Meal amino acids with varied levels of arginine do not affect postprandial vascular endothelial function in healthy young men. *The Journal of Nutrition* 137(6):1383-1389.

Martina V, Masha A, Gigliardi RV, Brocato L, Manzato E, Berchio A, Massarenti P, Settanni F, Casa LD, Bergamini S, Iannone A. 2008. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. *Diabetes Care* 31(5):940-944.

Maxwell AJ, Zapien MP, Pearce GL, MacCallum G, Stone PH. 2002. Randomized trial of a medical food for the dietary management of chronic stable angina. *Journal of American College of Cardiology* 39(1):37-45.

Mikami T, Onuma M, Hayashi TTA. 1974. Requirement of arginine for the replication of Marek's Disease herpes virus. *The Journal of General Virology* 22(1):115-128.

Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, Styles LA. 2000. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. *British Journal of Haematology* 111(2):498-500.

Morris CR, Morris SM, Hagar W, van Warmerdam J, Claster SKepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP. 2003. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? *American Journal of Respiratory and Critical Care Medicine* 168(1):63-69.

Naito T, Irei H, Tsujimoto K, Ikeda K, Arakawa T, Koyama AH. 2009. Antiviral effect of arginine against herpes simplex virus type 1. *International Journal of Molecular Medicine* 23(4):495-499.

Napoli C, Farzati B, Sica V, Iannuzzi E, Coppola G, Silvestroni A, Balestrieri ML, Florio A, Matarazzo A. 2008. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. *European Journal of Cardiovascular Prevention and Rehabilitation* 15(6):709-718.



Oka RK, Szuba A, Giacomini JC, Cooke JP. 2005. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. *Vascular Medicine* 10:265-274.

Oomen CM, van Erk J, Feskens EJM, Kok FJ, Kromhout D. 2007. Arginine intake and risk of coronary heart disease mortality in elderly men. *Arteriosclerosis, Thrombosis and Vascular Biology* 20(9):2134-2139.

Pallosi A, Fragasso G, Piatti P, Monti LD, Setola E, Valsecchi G, Galluccio E, Chierchia SL, Morgonato A. 2004. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. *The American Journal of Cardiology* 93(7):933-935.

Parnell MM, Holst DP, Kaye DM. 2005. Augmentation of endothelial function following exercise training is associated with increased L-arginine transport in human heart failure. *Clinical Science* 109(6):523-530.

Perusquía M, Villalón, Navarrete E, García GA, Pérez-Palacios G, Lemus AE. 2003. Vasodilating effect of norethisterone and its 5 α metabolites: a novel nongenomic action. *European Journal of Pharmacology* 475(1-3):161-169.

Peters N, Freilinger T, Opherck C, Pfefferkorn T, Dichgans M. 2008. Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. *Journal of Neurology* 255(8):1203-1208.

Polan ML, Hochberg RB, Trant AS, Wuh HCK. 2004. Estrogen bioassay of ginseng extract and Arginmax, a nutritional supplement for the enhancement of female sexual function. *Journal of Women's Health* 13(4):427-430.

Preli RB, Potvin Klein K, Herrington DM. 2002. Vascular effects of dietary L-arginine supplementation. *Atherosclerosis* 162(1):1-15.

Pretnar-Oblak J, Sabovic M, Zaletel M. 2007. Associations between systemic and cerebral endothelial impairment determined by cerebrovascular reactivity to L-arginine. *Endothelium* 14(2):73-80.

Rajapakse NW, Mattson DL. 2009. Role of L-arginine in nitric oxide production in health and hypertension. *Clinical and Experimental Pharmacology and Physiology* 36(3):249-255.

Ruel M, Beanlands RS, Lortie M, Chan V, Camack N, deKemp RA, Suuronen EJ, Rubens FD, DeSilva JN, Sellke FW, Steward DJ, Mesana TG. 2008. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: The Endothelial Modulation in Angiogenic Therapy randomized clinical trial. *The Journal of Thoracic and Cardiovascular Surgery* 135(4):762-770.

Rytlewski K, Olszanecki R, Lauterbach R, Grzyb A, Basta A. 2006. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: A preliminary study. *Basic &*



Clinical Pharmacology & Toxicology 99(2):146-152.

Rytlewski K, Olszanecki R, Lauterbach R, Grzyb A, Kiec-Wilk B, Dembinska-Kiec, Basta A. 2008. Effects of oral L-arginine on the pulsatility indices of umbilical artery and middle cerebral artery in preterm labor. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 138(1):23-28.

Santos RS, Pacheco MTT, Martins RABL, Vilaverde AB, Giana HE, Baptista F, Zângaro RA. 2002. Study of the effect of oral administration of L-arginine on muscular performance in healthy volunteers: An isokinetic study. *Isokinetics and Exercise Science* 10(3):153-158.

Shiraki T, Takamura T, Kajiyama A, Oka T, Saito D. 2004. Effect of short-term administration of high dose L-arginine on restenosis after percutaneous transluminal coronary angioplasty. *Journal of Cardiology* 44(1):13-20.

Siasos G, Tousoulis D, Vlachopoulos C, Antoniades C, Stefanadi E, Ioakeimidis N, Andreou I, Papavassiliou AG, Stefanadis C. 2008. Short-term treatment with L-arginine prevents smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. *International Journal of Cardiology* 126(3):394-399.

Siasos G, Tousoulis D, Vlachopoulos C, Antoniades C, Stefanadi E, Ioakeimidis N, Zisimos K, Siasou Z, Papavassiliou AG, Stefanadis C. 2009. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. *American Journal of Hypertension* 22(6):586-592.

Stanislavov R, Nikolova V. 2003. Treatment of erectile dysfunction with pycnogenol and L-arginine. *Journal of Sex & Marital Therapy* 29(3):207-213.

Stanislavov R, Nikolova V, Rohdewald P. 2008. Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. *International Journal of Impotence Research* 20(2):173-180.

Stein S, Todd P, Mahoney J. 1970. The arginine requirement for nucleocapsid maturation in Herpes simplex virus development. *Canadian Journal of Microbiology* 16(9):851-854.

Swanson B, Keithley JK, Zeller JM, Sha BE. 2002. A pilot study of the safety and efficacy of supplemental arginine to enhance immune function in persons with HIV/AIDS. *Nutrition* 18(78):688-690.

Tankersley RW Jr. 1963. Amino acid requirements of herpes simplex virus in human cells. *Journal of Bacteriology* 87(3):609-613.

Tausoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. 2002. L-Arginine in cardiovascular disease: dream or reality? *Vascular Medicine* 7(3):203-211.

Watanabe G, Tomiyama H, Doba N. 2000. Effects of oral administration of L-arginine on renal



function in patients with heart failure. *Journal of hypertension* 18(2):229-234.

Yin W-H, Chen J-W, Tsai C, Chiang M-C, Young MS, Lin S-J. 2005. L-Arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. *Clinical Nutrition* 24(6):988-997.